KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy

Drug Category : Array
Conference Category : Array
Lead Author : Dorsey, Mato, et al.
Published Date : 05/03/2017
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASCO%202017%20Dorsey%20Final.PDF
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top